BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: BD is a medical technology company operating in three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Q2 2009 revenues decreased 0.4% compared to Q2 2008. This decline was driven by a 5% unfavorable impact from foreign currency translation, partially offset by 3% volume growth and 2% hedge gains.
• Segment Performance:
  • Medical: Revenues decreased 3% due to foreign currency impacts and inventory reductions of insulin delivery devices.
  • Diagnostics: Revenues increased 2%, driven by growth in safety-engineered devices and cancer diagnostics, offset by a mild flu season.
  • Biosciences: Revenues increased 3%, with strong international growth offset by a slowdown in U.S. research spending.
• Profitability: Gross profit margin improved to 51.9% (from 51.1% prior year) due to favorable foreign currency translation and hedge gains. Operating income decreased slightly due to a significant litigation charge.
• Liquidity: Cash and equivalents decreased from $830.5 million to $542.7 million, primarily due to stock repurchases and working capital changes.

Guidance, Outlook, and Risks

Management Commentary and Unusual Items

• Antitrust Settlement: The company recorded a $45 million charge in Q2 2009 related to a settlement agreement with direct purchaser plaintiffs in antitrust class actions. This reduced income from continuing operations by approximately $28 million (11 cents per share).
• Foreign Exchange: The strengthening U.S. dollar significantly impacted results. Management expects gross profit margins to increase by about 150 basis points in 2009 compared to 2008.
• Capital Allocation: The company repurchased $342 million of common stock in the first six months of 2009. Capital expenditures are expected to be approximately $650 million for the full year.
• Outlook: Management anticipates R&D expenses to increase to 5.6%–5.8% of revenues in 2009. The reported tax rate for 2009 is expected to be about 27.3%.

Risks and Contingencies

• Legal Proceedings: Pending antitrust litigation with indirect purchasers continues. Other active matters include patent infringement claims (RTI), product liability suits (needlesticks, latex gloves), and a False Claims Act investigation.
• Economic Conditions: The global recession has slowed research-related capital spending in the U.S. (Biosciences segment) and impacted customer demand.
• Supply Chain: Risks associated with suppliers filing for bankruptcy (e.g., Lyondell Chemical) and potential disruptions in resin supply.
• Pandemic Risk: Potential for flu pandemics to disrupt manufacturing or increase demand for specific products.

Investor Verification Checklist

• Antitrust Settlement Status: Verify the final court approval of the $45 million direct purchaser settlement and the status of indirect purchaser claims.
• Foreign Exchange Sensitivity: Assess the impact of continued U.S. dollar strength on future revenue and margin projections.
• Supply Chain Resilience: Monitor the operational impact of supplier bankruptcies (e.g., Lyondell) on resin availability and production costs.
• Biosciences Demand: Track recovery in U.S. research funding and capital spending to validate revenue growth assumptions.
• Capital Return Policy: Confirm the remaining authorization for stock repurchases ($10.7 million shares remaining) and dividend sustainability.